-
Mashup Score: 65Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the ITMIG/ESTS Database - 20 hour(s) ago
R0 resection and radiation therapy have been associated with improved OS in thymic carcinoma (TC) patients. Here we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Lung Cancer in Syria - 3 day(s) ago
Syria is a low-income country located on the eastern shores of the Mediterranean Sea basin in the Middle East. The area of Syria is 185,180 km2 (Fig. 1).1 It consists of 14 governorates, and its capital is Damascus (Fig. 2). For the past 12 years, Syria has been experiencing conflict and economic crisis that have made the health system in general and cancer management in particular in a difficult situation.2
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
Syria, a country wrought w/conflict for over a decade, has faced significant obstacles in their healthcare system for years. Read about the nation's current state of #lungcancer care in this month's Lung Cancer Worldwide article. https://t.co/wCYMiM6xsD @MousaMAlali @MaherSaifo https://t.co/etgZkuAOcj
-
-
Mashup Score: 73
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 72
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib. - 11 day(s) ago
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pre-treatment and on-treatment circulating tumor DNA (ctDNA), as well as treatment-emergent alterations upon disease progression.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished. This is captured by the residual tumor (R) classification, which is separate from the TNM classification that describes the anatomic extent of a cancer independent of treatment. The traditional R-classification designates as R0 a complete resection, as R1 a macroscopically complete resection but with microscopic tumor at the surgical margin, and as R2 a resection that leaves gross tumor behind.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
This paper represents a comprehensive review of evidence regarding R categories & the descriptors thereof. W/the same overall framework & descriptors in the 9th edition, refinements to the descriptors should facilitate application & further research.https://t.co/Pqc8zM7djK #IASLC https://t.co/M8MHFkSSq3
-
-
Mashup Score: 21Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 18 day(s) ago
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion, exon 21 L858R), osimertinib remains the standard of care approved by the U.S. Food and Drug Administration in the first-line treatment of EGFR-mutated, advanced NSCLC. Despite continued efforts, disease progression remains inevitable with a high incidence of brain metastasis and poor prognosis for the patients harboring L858R.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 157
R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 157
R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 96Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review - 27 day(s) ago
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations is scattered and limited to mostly retrospective small cohorts, as these patients were usually excluded from clinical trials.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
Who benefits from post-operative radiation therapy (PORT) for thymic carcinoma? Analysis of 462 pts from ITMIG/ESTS database @JTOonline shows 5y OS rate 68% with PORT (vs 53%) with particular benefit for stage III-IV and those with R1/2 resection. https://t.co/jdcHDVOJq8